Targeting HER2-positive breast cancer: advances and future directions
SM Swain, M Shastry, E Hamilton - Nature reviews Drug discovery, 2023 - nature.com
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
Tumor microenvironment as a therapeutic target in cancer
Y **ao, D Yu - Pharmacology & therapeutics, 2021 - Elsevier
Tumor microenvironment denotes the non-cancerous cells and components presented in
the tumor, including molecules produced and released by them. The constant interactions …
the tumor, including molecules produced and released by them. The constant interactions …
Deciphering breast cancer: from biology to the clinic
Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
Pathogenesis of triple-negative breast cancer
F Derakhshan, JS Reis-Filho - Annual Review of Pathology …, 2022 - annualreviews.org
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …
fundamentally different diseases with different histologic, genomic, and immunologic …
Tertiary lymphoid structures in the era of cancer immunotherapy
Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-
lymphoid tissues at sites of chronic inflammation including tumours. Key common …
lymphoid tissues at sites of chronic inflammation including tumours. Key common …
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
C Denkert, G von Minckwitz, S Darb-Esfahani… - The lancet …, 2018 - thelancet.com
Summary Background Tumour-infiltrating lymphocytes (TILs) are predictive for response to
neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive …
neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive …
Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers
Purpose The aim of the current study was to conduct a pooled analysis of studies that have
investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple …
investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple …
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
The quantity of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is a robust
prognostic factor for improved patient survival, particularly in triple-negative and HER2 …
prognostic factor for improved patient survival, particularly in triple-negative and HER2 …
Breast cancer
N Harbeck, F Penault-Llorca… - Nature reviews …, 2019 - mayoclinic.elsevierpure.com
Breast cancer is the most frequent malignancy in women worldwide and is curable in~ 70–
80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with …
80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with …
Breast cancer immunotherapy: facts and hopes
LA Emens - Clinical cancer research, 2018 - AACR
Immunotherapy is revolutionizing the management of multiple solid tumors, and early data
have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 …
have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 …